Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Palivizumab biosimilar(mAbxience Research) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Palivizumab biosimilar(mAbxience Research): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market posit
9 min read
Interferon alfa-2b(Nautilus Biotech SA) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Interferon alfa-2b(Nautilus Biotech SA): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position
9 min read
Tocilizumab Biosimilar(Jiangsu Quanxin Biomedical Co Ltd) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Tocilizumab Biosimilar(Jiangsu Quanxin Biomedical Co Ltd): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deal
9 min read
Darbepoetin alfa biosimilar(CJ CheilJedang Corp.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Darbepoetin alfa biosimilar(CJ CheilJedang Corp.): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, marke
9 min read
Erythropoietin(Neose Technologies, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Erythropoietin(Neose Technologies, Inc.): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market positio
9 min read
Follitropin alfa biosimilar(JCR Pharmaceuticals Co., Ltd.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Follitropin alfa biosimilar(JCR Pharmaceuticals Co., Ltd.): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing dea
9 min read
Abatacept(Orban Biotech LLC) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Abatacept(Orban Biotech LLC): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key r
9 min read
Cetuximab biosimilar(Guilin Sanjin) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Cetuximab biosimilar(Guilin Sanjin): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, an
9 min read
Intravitreal ranibizumab(Sultan Qaboos University Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Intravitreal ranibizumab(Sultan Qaboos University Hospital): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing de
9 min read
Belatacept biosimilar (Alphamab) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Belatacept biosimilar (Alphamab): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and k
9 min read
Ramucirumab biosimilar (Henlius Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Ramucirumab biosimilar (Henlius Biotech): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market positio
9 min read
Ranibizumab Biosimilar (Beijing Jingyitaixiang Technology Development) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Ranibizumab Biosimilar (Beijing Jingyitaixiang Technology Development): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, l